Big picture - Why invest in Nemaura Medical Inc
Nemaura Medical Inc Snapshot
• SugarBEAT® commercial launch expected Q4 2018 in UK, Europe in H1 2019
o CE Mark approval expected 2018
o Completed 525 patient day European trial in Q4 2017
o CE Mark granted in 2016 on predecessor version
o FDA clinical program started Q2 2018, with expected completion in Q1 2019
• Active R&D pipeline
o SugarBEAT Gen II; pediatric label, improved accuracy, longer patch-wear time
o In-clinic variant of SugarBEAT; wired device compatible with hospital systems
o Platform technology can be used for broader applications beyond glucose monitoring
• Uplisted to NASDAQ in Q1 2018
o Improves access to capital markets while expanding pool of potential investors
Dr. Faz Chowdhury
Chief Executive Officer
Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical since formation in December 2013. He is sole inventor on more than 50 granted and pending patents across over 15 technology platforms within the medical device and pharmaceutical sectors. He has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier, and serves on the Board of Medilink East Midlands, UK. Dr. Chowdhury holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-medicine and drug delivery.
Chief Finance Officer
Mr. Anderson has served as CFO of Nemaura Medical since December 2016. He qualified as a Chartered Certified Accountant in 1992 whilst working for Touche Ross (now Deloitte), and has worked in industry for more than 20 years with a diverse range of companies, including subsidiaries of publicly-owned corporations such as Hitachi, TriMas Corporation, Precision Castparts Corporation and Hospira Inc. Mr. Anderson received an MBA from Loughborough University in 1999.
Mr. Bashir Timol
Chief Business Officer
Mr. Timol has served as member of the board of Nemaura Medical since formation in December 2013, and CBO since April 2018. He has co-founded, managed and funded several biotech and life science companies, and led the investment consortium that provided capital for the initial two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.
Professor Karrar Khan
Director of Product Development
Professor Karrar Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK. His expertise range from development for phase 1 to phase 3- 4 and significant experience of bringing prescription and OTC products to market on a global level (and has contributed to the registration and launch of over 60 pharmaceutical products). He is a Qualified person under the EC quality assurance directive.
Director of Commercial Development and Licensing
David Scott is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has also provided licensing training for a number of multinational pharma companies and training organisations and has published widely, (he is the author of the best-selling report, “Scrip’s Practical Guide to Pharmaceutical Licensing”). David is also an accredited “Certified Licensing Professional”.
Dr Richard Toon
Technical and Business Development Manager
Dr. Richard Toon is a chartered chemist who originally trained as a synthetic chemist and more recently trained in law. He has over 20 years of experience within pharmaceutical drug development including a number of years supervising ‘blue skies’ research projects for potential commercial exploitation within two large multinational Pharmaceutical Companies in the UK. More recently his career has focused on commercial law activities, such as contract negotiation and intellectual property issues, and business development. He has completed a number of large scale grant applications for industrial research, and is author of numerous publications pertaining to pharmaceutical development, and is also a Fellow of the Royal Society of Chemistry.
Advanced Technology Innovation Centre
Loughborough University Science and Enterprise Parks 5 Oakwood Drive
Loughborough LE11 3QF
+44 1509 222912